Oxygenta Pharmaceutical Ltd (BSE: 524636) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹174 Cr, it ranks #2,781 by market cap among the 6,137 Indian listed companies on FinBizNet, and #38 of 63 in Pharmaceuticals. At ₹46.07 (as of 25 Oct 2026), the share price is 35.6% below its 52-week high of ₹71.59 and 7.1% above its 52-week low of ₹43.00. The share price is down 23.0% over one year and down 9.5% over three months.
| Current Price | ₹46.07 |
|---|---|
| Market Cap | ₹174 Cr |
| BSE Code | 524636 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | -9.8 |
| Return on Equity | 51.90% |
| Return on Assets | -10.72% |
| 52-Week Range | ₹43.00 – ₹71.59 |
| 1-Year Price Change | -23.0% |
| 3-Month Price Change | -9.5% |
| Beta (1Y) | 0.64 |
| Headquarters | Hyderabad, Telangana |
| Website | www.oxygentapharma.com |
Oxygenta Pharmaceutical Limited manufactures and sells pharmaceutical, medical, and veterinary preparations in India. It offers active pharmaceuticals ingredients and commercial intermediates. The company was formerly known as S.S. Organics Limited and changed its name to Oxygenta Pharmaceutical Limited in February 2022. Oxygenta Pharmaceutical Limited was incorporated in 1990 and is based in Hyderabad, India.
1. Pharmaceuticals-This segment engages in the manufacture and marketing of bulk drugs and intermediates in India. It produces quinolones, anti-asthmatic, anti-ulcerant, and anti-inflammatory drugs.
1. Manufacturing of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Oxygenta Pharmaceutical Ltd | ₹174 Cr | -9.8 | 51.90% | — | -23.0% |
Listed by market capitalisation. Ratios are shown for context only.
Oxygenta Pharmaceutical Ltd is trading at ₹46.07, with a market capitalisation of ₹174 Cr.
Oxygenta Pharmaceutical Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Oxygenta Pharmaceutical Ltd has a P/E of -9.8 and a return on equity of 51.90%.
Oxygenta Pharmaceutical Ltd is listed on the BSE under the scrip code 524636.
Oxygenta Pharmaceutical Ltd's share price is down 23.0% over one year and down 9.5% over three months. Its 52-week range is ₹43.00 to ₹71.59.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.